Zurzuvae PPD denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for zurzuvae ppd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Issue a "Not FDA-Approved" Denial for Zurzuvae in PPD

This denial type is often issued in error or reflects a coding or administrative mismatch rather than a genuine regulatory dispute. Zurzuvae (zuranolone) does hold FDA approval — it was approved by the FDA for major depressive disorder (MDD) in adults, and postpartum depression is a recognized population within that indication. If you have received this denial, the most likely explanations are: (1) the claim was coded in a way that did not align with the approved indication, (2) the plan's formulary system has not been updated to reflect the approval, or (3) the plan is applying an outdated internal policy.

## Why This Denial Is Appealable

A denial claiming a drug lacks FDA approval when it demonstrably holds that approval is a factual error and a legally reviewable adverse benefit determination. Under ACA §2719 and ERISA §503, you have the right to a full-and-fair review by a reviewer who has not been involved in the original denial decision. Supplying the FDA approval documentation directly is often sufficient to reverse this denial at the internal appeal stage.

## Federal Appeal Framework

• Internal appeal: File immediately upon receiving the denial notice — do not wait. Include FDA approval documentation as Exhibit A. Aetna must respond within the plan's stated internal appeal timeframe.
• External review (ACA §2719): If the internal appeal is denied despite clear FDA approval evidence, request independent external review within approximately 4 months of the final internal denial. An accredited IRO will evaluate the clinical and regulatory record.
• Expedited review: If postpartum symptoms pose an urgent risk to health or safety, request expedited processing at both the internal and external levels simultaneously; decisions are required within 72 hours.

## Documentation to Gather

1. FDA approval confirmation: The FDA drug label and approval letter for Zurzuvae (zuranolone), publicly available from the FDA's official website (drugs.fda.gov). Print and attach as Exhibit A. 2. Prescribing indication alignment: A letter from the prescriber confirming the patient's diagnosis aligns with the FDA-approved indication (MDD in adults, PPD population). 3. Claim coding review: Ask your provider's billing department to confirm the NDC code and ICD-10 diagnosis code submitted on the claim match the approved indication. 4. Denial letter analysis: Quote the specific language Aetna used to assert non-approval, and address it factually and directly in your appeal letter. 5. Aetna policy update request: In your appeal, formally request that Aetna review and update any internal policy that may not yet reflect the current FDA approval status.

## Criteria-Mapping Structure

In your appeal letter, structure your response as:

• Aetna's stated basis for denial: [quote verbatim]
• Factual rebuttal: [FDA approval date, indication, reference to the official label]
• Patient-specific documentation: [diagnosis, prescriber confirmation, claim codes]

Keep the tone factual and documentary rather than adversarial. Errors of this type are often corrected at the first internal appeal level when clearly documented evidence is presented.